OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma

OPKO HEALTH, INC.

2025-FY EPS reported -$0.08 vs consensus -$0.07 ▼ miss (-15.4%)

Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.
Pharma segment operating loss narrowed to $2.1M from $16.0M; IP transfer revenue rose to $43.1M (includes $12.5M Merck milestone, $23.8M BARDA).
Diagnostics revenue fell to $103.1M from $124.2M on asset sales; operating loss improved to $21.7M from $42.3M.
BARDA awarded additional $51M for COVID/influenza antibodies; total awards to ModeX now $110M, up to $205M if all options exercised.
Capital actions: repurchased $17M principal notes, 10.9M shares for $16.5M; reduced share count 10% in 2024; sold part of BioReference for $237.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.